Overview

GC012F in Patients With Autoimmune Diseases

Status:
NOT_YET_RECRUITING

Trial end date:
2029-03-31

Target enrollment:

Participant gender:

Summary

This is an open-label, early exploratory main clinical study to evaluate the safety and efficacy of GC012F Injection in subjects with autoimmune diseases (AID), as well as to assess its pharmacokinetic (PK) and pharmacodynamic (PD) profiles.

Phase:

EARLY_PHASE1

Details

Lead Sponsor:

Qiong Fu

Collaborator:

Gracell Biotechnologies (Shanghai) Co., Ltd.